Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease

18 February 2023 : Clinical Research

Tomislav Jukic^1CDEF, David Drobne^2ABCDE, Sasa Pusavec^3BF, Alojz Ihan^3AE, David Stubljar^4ACDE*, Andrej Starc^5DE

DOI: 10.12659/MSM.939084

Med Sci Monit 2023; 29:e939084

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Basic characteristics of patients whose samples were included in analysis.

	All patients (N=32)
Gender
Male/Female	15 (46.9%)/17 (53.1%)
Age [years]	27.5
IBD phenotype
Crohn’s disease	19 (59.4%)
Ulcerative colitis	13 (40.6%)
Location
L1: terminal ileal/limited cecal disease	2 (5.2%)
L2: colonic	19 (59.4%)
L3: ileocolonic	11 (34.2%)
L4: upper disease	0
Years from diagnosis till start of IFX
0–5	11 (34.2%)
5–10	9 (28.1%)
>10	12 (37.5%)

Back to the Article